Precision BioSciences, Inc.
DTILHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. With a market capitalization of $183.3M, it sits in micro-cap territory. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Market Cap
$183.3M
Beta
1.27
P/E (TTM)
—
P/E (Fwd)
-3.57
EPS (TTM)
$-1.35
EPS (Fwd)
$-1.86
ROE
-135.2%
ROA
-19.4%
Cash
$87.5M
Total Debt
$28.1M
Free CF
-$16.3M
52W Change
-1.2%
Annual Financials
Cash vs Debt
Where DTIL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DTIL finished 13.31% below its 150-day moving average ($7.14) and 3.43% below its 200-day moving average ($6.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DTIL overbought or oversold?
At the October 20, 2026 close, DTIL's RSI(14) was 50.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $87.5M in cash comfortably exceeding the $28.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$16.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -135.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.1M (2022) to $34.3M (2025), reflecting a 37% increase over the period.
With cash comfortably exceeding debt, DTIL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing DTIL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.